Effects of sustained antiangiogenic therapy in multistage prostate cancer in TRAMP model.

Effects of sustained antiangiogenic therapy in multistage prostate cancer in TRAMP model. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Effects of sustained antiangiogenic therapy in multistage prostate cancer in TRAMP model. Abstract Text:

Tatyana Isayeva,Diptiman Chanda,Lisa Kallman,Isam-Eldin A Eltoum,Selvarangan Ponnazhagan,

Antiangiogenic therapy is a promising alternative for prostate cancer growth and metastasis and holds great promise as an adjuvant therapy. The present study evaluated the potential of stable expression of angiostatin and endostatin before the onset of neoplasia and during the early and late stages of prostate cancer progression in transgenic adenocarcinoma of mouse prostate (TRAMP) mice. Groups of 5-, 10-, and 18-week-old male TRAMP mice received recombinant adeno-associated virus-6 encoding mouse endostatin plus angiostatin (E+A) by i.m. injection. The effects of therapy were determined by sacrificing groups of treated mice at defined stages of tumor progression and following cohorts of similarly treated mice for long-term survival. Results indicated remarkable survival after recombinant adeno-associated virus-(E+A) therapy only when the treatment was given at an earlier time, before the onset of high-grade neoplasia, compared with treatment given for invasive cancer. Interestingly, early-stage antiangiogenic therapy arrested the progression of moderately differentiated carcinoma to poorly differentiated state and distant metastasis. Immunohistochemical analysis of the prostate from treated mice indicated significantly lower endothelial cell proliferation and increased tumor cell apoptosis. Vascular endothelial growth factor receptor (VEGFR)-2 expression was significantly down-regulated in tumor endothelium after treatment but not VEGFR-1. Analysis of the neuroendocrine marker synaptophysin expression indicated that antiangiogenic therapy given at an early-stage disease reduced neuroendocrine transition of the epithelial tumors. These studies indicate that stable endostatin and angiostatin gene therapy may be more effective for minimally invasive tumors rather than advanced-stage disease.

Effects of sustained antiangiogenic therapy in multistage prostate cancer in TRAMP model. Publishing Authors By Initials

T Isayeva,D Chanda,L Kallman,IE Eltoum,S Ponnazhagan,

For similar membrane glycoproteins: synaptophysin research abstracts see: membrane glycoproteins: synaptophysin research

PUBMED ID PMID:

MEDLINE DATE:

Effects of sustained antiangiogenic therapy in multistage prostate cancer in TRAMP model. Journal Published:

PUBLICATION TYPE: Research Support, U.S. Gov't,

Journal: Cancer research

VOLUME: 67

Page Numbers: 5789-97

Journal Abbreviation: Cancer Res.

ISSN: 0008-5472

DAY: 15

MONTH: Jun

YEAR: 2007

Effects of sustained antiangiogenic therapy in multistage prostate cancer in TRAMP model. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 2984705

Effects of sustained antiangiogenic therapy in multistage prostate cancer in TRAMP model. Keywords Mesh Terms:

KEYWORDS: Synaptophysin

MESH TERMS: metabolism

Chemical & Substance for Abstract: Effects of sustained antiangiogenic therapy in multistage prostate cancer in TRAMP model. Information

Substance Name: Receptors, Vascular Endothelial Growth F

Registry Number: EC 2.7.1.112

Grant and Affiliation Information for Effects of sustained antiangiogenic therapy in multistage prostate cancer in TRAMP model.

AFFILIATION: Department of Pathology, The University of Alabama at Birmingham, Birmingham, Alabama 35294-0007, USA.

Country: United States

AGENCY: United States NCI

GRANT: R01CA98817

ACRONYM: CA

MEDLINETA: Cancer Res

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Effects of sustained antiangiogenic therapy in multistage prostate cancer in TRAMP model Related Publications

• Airway epithelium directed gene therapy for cystic fibrosis.
• Bone homing of mesenchymal stem cells by ectopic alpha4 integrin expression.
• Effects of sustained antiangiogenic therapy in multistage prostate cancer in TRAMP model.
• Intraperitoneal gene therapy by rAAV provides long-term survival against epithelial ovarian cancer independently of survivin pathway.
• Silencing of Transforming Growth Factor-{beta}1 In situ by RNA Interference for Breast Cancer: Implications for Proliferation and Migration In vitro and Metastasis In vivo.
• Systemic osteoprotegerin gene therapy restores tumor-induced bone loss in a therapeutic model of breast cancer bone metastasis.
• Therapeutic Potential of Mesenchymal Stem Cells Producing Interferon-{alpha} in a Mouse Melanoma Lung Metastasis Model.
• Therapeutic potential of genetically modified mesenchymal stem cells.